The mechanism by which these biological differences contribute to lung cancer differences and sensitivity to PD-1/PD-L1 therapies is likely multi-factorial, with cell autonomous and non-cell autonomous immune effects contributing. The gene discussed is PDCD1; the disease is lung cancer.